- Home
- BOLD vs PLUR Comparison
BOLD vs PLUR Comparison
Compare BOLD & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BOLD | PLUR |
|---|---|---|
| Founded | 2018 | 2001 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.4M | 28.4M |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | BOLD | PLUR |
|---|---|---|
| Price | $1.22 | $3.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $4.00 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 125.9K | 12.0K |
| Earning Date | 11-05-2025 | 02-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,326,000.00 |
| Revenue This Year | N/A | $97.38 |
| Revenue Next Year | N/A | $293.97 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 121.74 |
| 52 Week Low | $1.00 | $2.82 |
| 52 Week High | $2.54 | $7.13 |
Technical Indicators
Market Signals| Indicator | BOLD | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 46.13 | 53.66 |
| Support Level | $1.19 | $3.00 |
| Resistance Level | $1.31 | $3.50 |
| Average True Range (ATR) | 0.07 | 0.18 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 12.50 | 66.10 |
Price Performance
Historical ComparisonAbout BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.